Semaglutide® providers &
prescriptions in New Haven, CT
Verified Semaglutide providers in New Haven, CT. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Semaglutide provider in Connecticut.
Every entry is checked against the NPI registry and the Connecticut medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Semaglutide in New Haven.
33 GLP-1 prescribers and 7 local resource types are on record for New Haven, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Connecticut’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.
Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]
In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]
Community health · CDC
Weight & metabolic health in Connecticut
Diagnosed diabetes reaches 8.4% of adults in Connecticut.
- of Connecticut adults have obesity
- 32%
- diagnosed diabetes
- 8.4%
Age-adjusted estimates for Connecticut, community figures, not individual risk. CDC BRFSS 2024.
The prescription is one part. Here is the rest, in New Haven.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near New Haven, CT, ordered as the registry lists them, never by who pays us.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
480 Sherman Pkwy
33 Hull St 3rd Floor
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
1 Park St Fl 2
What the trials actually showed.
We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]